Z
Zijun Y. Xu-Monette
Researcher at Duke University
Publications - 120
Citations - 6732
Zijun Y. Xu-Monette is an academic researcher from Duke University. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 36, co-authored 110 publications receiving 5422 citations. Previous affiliations of Zijun Y. Xu-Monette include Durham University & Guangzhou Medical University.
Papers
More filters
Journal ArticleDOI
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Green,Ken H. Young,Carlo Visco,Zijun Y. Xu-Monette,Attilio Orazi,Ronald S. Go,Ole John Nielsen,Ole V. Gadeberg,Torben Mourits-Andersen,Mikael Frederiksen,Lars Moller Pedersen,Michael Boe Møller +11 more
TL;DR: The immunohistochemical DHS defined a large subset of DLBCLs with double-hit biology and was strongly associated with poor outcome in patients treated with R-CHOP.
Journal ArticleDOI
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu,Zijun Y. Xu-Monette,Alexander Tzankov,Tina Green,Lin Wu,Aarthi Balasubramanyam,Wei-Min Liu,Carlo Visco,Yong Li,Roberto N. Miranda,Santiago Montes-Moreno,Karen Dybkær,April Chiu,Attilio Orazi,Youli Zu,Govind Bhagat,Kristy L. Richards,Eric D. Hsi,William W.L. Choi,Xiaoying Zhao,J. Han van Krieken,Qin Huang,Jooryung Huh,Weiyun Z. Ai,Maurilio Ponzoni,Andrés J.M. Ferreri,Fan Zhou,Graham W. Slack,Randy D. Gascoyne,Meifeng Tu,Daina Variakojis,Weina Chen,Ronald S. Go,Miguel A. Piris,Michael Boe Møller,L. Jeffrey Medeiros,Ken H. Young +36 more
TL;DR: It is concluded that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL.
Journal ArticleDOI
Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients
Roberto N. Miranda,Tariq N. Aladily,H. Miles Prince,Rashmi Kanagal-Shamanna,Daphne de Jong,Luis Fayad,Mitual Amin,Nisreen Haideri,Govind Bhagat,Glen S. Brooks,David A. Shifrin,Dennis P. O'Malley,Chan Yoon Cheah,Carlos E. Bacchi,Gabriela Gualco,Shiyong Li,John A. Keech,Ephram P. Hochberg,Matthew J. Carty,Summer E. Hanson,Eid Mustafa,Steven Sanchez,John T. Manning,Zijun Y. Xu-Monette,Alonso R. Miranda,Patricia S. Fox,Roland L. Bassett,Jorge J. Castillo,Brady E Beltran,Jan de Boer,Zaher Chakhachiro,Dongjiu Ye,Douglas P. Clark,Ken H. Young,L. Jeffrey Medeiros +34 more
TL;DR: Most patients with breast implant-associated ALCL who had disease confined within the fibrous capsule achieved complete remission, justifying cytotoxic chemotherapy in addition to removal of implants.
Journal ArticleDOI
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
Davide Rossi,Valeria Spina,Clara Deambrogi,Silvia Rasi,Luca Laurenti,Kostas Stamatopoulos,Luca Arcaini,Marco Lucioni,Gabrielle B. Rocque,Zijun Y. Xu-Monette,Carlo Visco,Julie Chang,Ekaterina Chigrinova,Francesco Forconi,Roberto Marasca,Caroline Besson,Theodora Papadaki,Marco Paulli,Luigi Maria Larocca,Stefano Pileri,Valter Gattei,Francesco Bertoni,Robin Foà,Ken H. Young,Gianluca Gaidano +24 more
TL;DR: The molecular dissection of RS into biologically distinct categories highlights the genetic heterogeneity of this disorder and provides clinically relevant information for refining the prognostic stratification of patients.
Journal ArticleDOI
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study
Carlo Visco,Yong Li,Zijun Y. Xu-Monette,Roberto N. Miranda,Tina Green,Alexandar Tzankov,Wanqing Wen,W-m Liu,Brad S. Kahl,Emanuele S.G. d'Amore,Santiago Montes-Moreno,Karen Dybkær,A Chiu,Wayne Tam,Attilio Orazi,Youli Zu,Govind Bhagat,Jane N. Winter,H-Y Wang,Stacey S O'Neill,Cherie H. Dunphy,Eric D. Hsi,Xianfeng Frank Zhao,Ronald S. Go,William W.L. Choi,Feng Zhou,Magdalena Czader,J. Tong,Xiaoying Zhao,J.H.J.M. van Krieken,Qin Huang,Weiyun Z. Ai,Joan E. Etzell,M. Ponzoni,Anna Ferreri,M A Piris,Michael Boe Møller,C. E. Bueso-Ramos,L J Medeiros,Lin Wu,Ken H. Young +40 more
TL;DR: An algorithm based on the expression of CD10, FOXP1 and BCL6 was developed that had a simpler structure than other recently proposed algorithms and 92.6% concordance with GEP and effectively predicts prognosis of DLBCL patients matching GEP subgroups in the era of rituximab therapy.